Screener
Vera Therapeutics VERA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | (7,966) | 1,597 |
| Accrued and other liabilities | (437) | (4,782) |
| Operating lease liabilities | (182) | (394) |
| Net cash used in operating activities | (106,500) | (54,406) |
| Cash flows from investing activities | ||
| Upfront and milestone payments under license agreements | (15,000) | (750) |
| Purchase of internal use software license | (150) | — |
| Purchase of property and equipment | (23) | (187) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's operating cash flow?
- Vera Therapeutics (VERA) reported operating cash flow of -$106.5M in Q1 2026.
- How has Vera Therapeutics's operating cash flow changed year-over-year?
- Vera Therapeutics's operating cash flow decreased by 95.8% year-over-year, from -$54.41M to -$106.5M.
- What is the long-term trend for Vera Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Vera Therapeutics's operating cash flow has grown at a 78.6% compound annual growth rate (CAGR), from -$23.71M to -$241.1M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Vera Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude